AlphaGen Therapeutics Launches with Seed Financing to Develop Novel Targeted Radioligand Therapies - October 15, 2023

AlphaGen Therapeutics Co., Ltd. (hereinafter referred to as "AlphaGen Therapeutics") announced today that it has completed a seed round financing of tens of millions of dollars jointly led by Sidao Capital and its sister funds. As a company that focuses on innovative targeting of radioligand drugs (RLT), Nuclear Boat Pharmaceutical is committed to the research and development, innovation, and industrialization of the next generation of radiopharmaceuticals.

AlphaGen Therapeutics was jointly incubated and established by a team of investors with rich experience in incubating startups, in collaboration with Professor Cheng Zhen, a leading scientist in the field of radioactive drugs. The company has built a product pipeline with innovative nuclide Pb 212 as its core, among which the leading product has entered the early clinical development stage and is expected to become China's first Pb 212 radioactive drug. In the future, the company will continue to build a pipeline of next-generation innovative radiation therapy products. This round of seed round financing will help AlphaGen Therapeutics rapidly promote the clinical development of the Pb-212 pipeline, and build a leading radioactive drug research and development technology platform as well as future pipelines.

The global radiopharmaceutical market has a scale of up to $7 billion and is currently in a phase of rapid growth, including α Radiopharmaceuticals, as emerging therapies, are leading the next wave of innovation in the field of nuclear medicine. However, currently there is a lot of research and leading clinical progress in European and American countries α Nuclides are usually dominated by actinide 225 (Ac-225). The supply of this nuclide is extremely limited globally, posing significant challenges to clinical drug supply and commercial production. The dilemma of insufficient supply of nuclides is particularly prominent in the Chinese market. Due to the severe lack of domestic production capacity, many other therapeutic nuclides such as lutetium-177 (Lu-177) are also facing a shortage of supply, leading to challenges in the production, clinical supply, and commercialization of nuclear drugs in China. Pb 212 is a new type α Nuclide, AlphaGen Therapeutics has highly innovative Pb-212 separation and purification technology, which can achieve stable large-scale production and supply of Pb-212, thereby solving other problems α The problem of limited supply faced by nuclides.

TIn addition, Professor Cheng Zhen, a world-famous scientist in the field of radiopharmaceuticals and director of the Molecular Imaging Center of the Chinese Academy of Sciences Shanghai Institute of Materia Medica (SIMM), officially joined AlphaGen Therapeutics as the co-founder of science and chairman of the Scientific Advisory Board (SAB). Professor Cheng is a Fellow of the Royal Society of Chemistry (RSC) and the International Society for Optical Engineering (SPIE) in the UK. His research focuses on the discovery and development of new integrated diagnostic and therapeutic reagents, non-invasive imaging technologies, and biological nanotechnology for early detection and treatment of cancer. Before joining the Chinese Academy of Sciences Shanghai Institute of Materia Medica, Professor Cheng had long served in the Stanford University Molecular Imaging Center (MIPS), Bio-X Center, Clary Stanford Cancer Early Detection Research Center and the Department of Radiology, and served as an associate professor of radiology. He has also served as the President of the Chinese American Society for Nuclear Medicine and the Society for Molecular Imaging, as well as a member of the American Society for Nuclear Medicine and Molecular Imaging (SNMMI). As the co-founder of the company, Professor Cheng will deeply participate in and guide the strategic planning and pipeline construction of AlphaGen Therapeutics.

About AlphaGen Therapeutics

AlphaGen Therapeutics was jointly incubated and founded by Stodo Capital and Professor Cheng Zhen, a leading scientist in the field of radiopharmaceuticals. It is a radiopharmaceutical company that focuses on the research, development, innovation, and industrialization of innovative targeted radioligand therapies. AlphaGen Therapeutics is committed to utilizing its leading technology platform to develop targeted radiopharmaceutical therapies for patients in China and globally. For more details, please visit the company's official website www.alphagentx.com or follow the "AlphaGen Therapeutics" official account on WeChat.

About EIGHT ROADS

EIGHT ROADS is a global venture capital firm backed by Fidelity Group, with investment teams covering China, India, Japan, Europe, and the United States, with total asset management exceeding 11 billion US dollars. Sidao Capital has 50 years of venture capital experience and has invested in over 300 companies in the healthcare and technology innovation fields worldwide, including Alibaba, Beam Therapeutics, Xiaoma Zhixing, Xinda Biotechnology, Yingsi Intelligence, HiBob, Sipai Group, Semma Therapeutics, WuXi AppTec, and others.